2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOX
2023
Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study
Lebwohl B, Ma C, Lagana S, Pai R, Baker K, Zayadi A, Hogan M, Bouma G, Cellier C, Goldsmith J, Lundin K, Pinto-Sanchez M, Robert M, Rubio-Tapia A, Sanders D, Schaeffer D, Semrad C, Silvester J, Verdú E, Verma R, Wu T, Feagan B, Crowley E, Jairath V, Murray J. Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study. Gastroenterology 2023, 166: 88-102. PMID: 37704112, DOI: 10.1053/j.gastro.2023.08.051.Peer-Reviewed Original ResearchConceptsRandomized controlled trialsSecondary patient-reported outcome measuresOutcome measuresRandomized controlled trial designPatient-reported outcome measuresControlled trialsGluten challengeStandard Randomized Controlled TrialPatient-reported outcomesGluten-free dietReversal of histological changesMethods studyCeliac diseaseEligibility criteriaHistological end pointsPrevention of relapseEffective pharmacological optionsAppropriate studiesTrial outcomesExclusion criteriaClinical trial designTrial designTreatment of celiac diseasePediatric patientsPharmacological options